Yaz Birth Control Side Effects

Most Common Side Effects

Yaz (drospirenone 3mg/ethinyl estradiol 20mcg) causes breakthrough bleeding or spotting in approximately 25% of users during the first 2-3 cycles, but this typically resolves spontaneously without requiring discontinuation. 1, 2

Frequent Adverse Effects (First 3 Cycles)

Breakthrough bleeding/spotting: 24.9% in PMDD trials, 4.7% in contraception/acne trials—most common during cycles 1-3 and usually self-resolving 2
Nausea: 2.6% of users; advise taking with food or at bedtime as symptoms typically resolve within first few cycles 2, 3
Breast pain/tenderness: 2.3-2.6% of users 2, 3
Breast swelling: 1.3% of users 3
Headache: Common but typically transient 1, 2

Gastrointestinal Effects

Abdominal bloating, cramps, and nausea 1
Vomiting and appetite changes 1
Weight changes (can be gain or loss) 1

Neuropsychiatric Effects

Depression and mood changes 1
Migraine headaches 1
Nervousness 1

Other Common Effects

Edema (fluid retention) 1
Vaginal candidiasis 1
Cervical secretion changes 1

Serious Adverse Effects Requiring Immediate Discontinuation

Venous Thromboembolism (VTE)—The Most Critical Risk

Drospirenone-containing contraceptives carry a VTE incidence of approximately 10 per 10,000 woman-years, representing a 50-80% higher risk compared to levonorgestrel-containing pills (hazard ratio 1.77,95% CI 1.33-2.35). 2, 4

Background VTE rate in non-users: 2 per 10,000 person-years 2
Standard low-dose estrogen COCs: 6 per 10,000 woman-years 2
Yaz specifically: 10 per 10,000 woman-years 2
The elevated risk is attributed specifically to the drospirenone component 2

Emergency signs requiring immediate cessation and urgent evaluation:

Sudden severe leg pain, swelling, warmth, or redness (DVT) 1, 2
Sudden shortness of breath or chest pain (pulmonary embolism) 1, 2

Cardiovascular Events

Absolute attributable risk for major cardiovascular events (MI, stroke): 2 per 10,000 person-years 2
Immediate cessation required for: Chest pain, jaw pain, diaphoresis (MI signs) 2
Immediate cessation required for: Sudden severe headache, visual changes, weakness, slurred speech (stroke signs) 2
Hypertension (though drospirenone uniquely may lower BP by 1-4 mmHg in most users) 1, 2

Neurological Emergencies

New-onset migraine with aura or focal neurologic symptoms is an absolute contraindication requiring prompt discontinuation 2
Cerebral thrombosis 1

Hepatic Complications

Cholestatic jaundice 1
Hepatic adenomas or carcinomas 1

Other Serious Effects

Anaphylaxis 1
Systemic lupus erythematosus exacerbation 1
Porphyria exacerbation 1

Absolute Contraindications (Do Not Prescribe If Present)

Thrombotic/Cardiovascular Contraindications

History of deep vein thrombosis or pulmonary embolism 1, 2
Current or history of cerebrovascular disease or stroke 1, 2
Coronary artery disease or myocardial infarction 1, 2
Uncontrolled hypertension (note: drospirenone may lower BP only when already controlled) 1, 2
Smoking combined with age ≥35 years 1, 2
Hypercoagulopathies 1
Thrombogenic valvular or rhythm diseases 1
Migraine with focal neurologic symptoms at any age, or migraine without aura in women ≥35 years 1, 2
Surgery with prolonged immobilization 1

Malignancy Contraindications

Breast cancer or other estrogen/progestin-sensitive cancers 1, 2
Carcinoma of the endometrium 1

Hepatic Contraindications

Active or severe liver disease (hepatitis, cirrhosis) 1, 2
Hepatic adenomas or carcinomas 1, 2
Hepatocellular disease with abnormal liver function 1
Cholestatic jaundice of pregnancy or jaundice with previous pill use 1

Renal/Metabolic Contraindications (Unique to Drospirenone)

Renal dysfunction 1
Adrenal insufficiency 1

Other Absolute Contraindications

Pregnancy (Category X) 1
Undiagnosed genital/uterine bleeding 1
Hypersensitivity or anaphylactic reaction to components 1

Unique Metabolic Effects of Drospirenone

Blood Pressure Effects (Beneficial in Most Cases)

Unlike other progestins that may elevate blood pressure, drospirenone's antimineralocorticoid activity decreases systolic blood pressure by 1-4 mmHg in most users. 2, 4

In one 12-month study: mean systolic BP fell from 109.2 mmHg to 103.4 mmHg 2
In women with baseline systolic BP ≥130 mmHg taking 4mg drospirenone progestin-only pill: systolic BP dropped by approximately 8 mmHg 2, 4
This distinguishes drospirenone from other synthetic progestins that may increase BP 4

Hyperkalemia Risk (Minimal in Healthy Women)

Large retrospective cohort analyses found no increased risk of hyperkalemia with drospirenone-containing COCs compared to other COCs, even when combined with spironolactone. 2

Among 5,752 patients taking drospirenone COCs plus spironolactone: hyperkalemia rates were not significantly elevated 2
Routine serum potassium monitoring is NOT required in healthy women 2
Contraindicated only in women with renal dysfunction or adrenal insufficiency 1

Cancer Risk Profile (Protective Overall)

Combined oral contraceptives including Yaz are associated with a 29% reduction in gynecologic malignancies and a net decrease in overall cancer risk. 2

Significant risk reductions for: Colon, uterine, and ovarian cancers 2
Evidence on breast cancer risk is mixed, but overall cancer-related mortality appears lower with COC use 2

Drug Interactions (Extensive List)

Medications That Reduce Yaz Effectiveness

Rifampin and griseofulvin (only antiinfectives proven to reduce COC effectiveness) 1
Anticonvulsants: barbiturates, carbamazepine, phenytoin, primidone, topiramate 1
HIV protease inhibitors: amprenavir, nelfinavir, ritonavir, fosamprenavir, tipranavir 1
Other: modafinil, nevirapine, St. John's wort, bosentan, bexarotene 1

Important Clarification on Antibiotics

The tetracycline class of antibiotics (commonly used for acne) has NOT been shown to reduce COC effectiveness when taken concomitantly. 1

Medications Affected by Yaz

Anticoagulants (warfarin, vitamin K antagonists) 1
Tranexamic acid 1
Angiotensin II receptor blockers 1
Lamotrigine (levels may decrease) 1
Theophylline, alprazolam, fentanyl (levels may increase) 1

Drospirenone-Specific Interactions

Because drospirenone is a spironolactone analog, there was theoretical concern about combining it with spironolactone for hyperkalemia risk. However, one study of 27 women taking Yaz plus spironolactone 100mg daily showed no significant potassium elevations and no additional side effects requiring discontinuation. 1

Clinical Decision Algorithm: When to Choose Yaz vs. Alternatives

Choose Yaz When:

Patient requires oral contraception AND has moderate acne vulgaris (FDA-approved indication for women ≥14 years post-menarche) 2, 4
Patient needs contraception AND would benefit from modest blood pressure reduction (controlled hypertension or high-normal BP) 2, 4
Patient has no VTE risk factors and specifically desires drospirenone's unique properties 2

Choose Levonorgestrel-Containing Pills Instead When:

Patient has ANY VTE risk factors (personal/family history, obesity, smoking, age >35, thrombophilia) 2
Patient does not specifically need drospirenone's unique properties (acne control, BP reduction) 2
Lower VTE risk is priority (levonorgestrel has 50-80% lower VTE risk than drospirenone) 2, 4

Consider Non-Hormonal or Progestin-Only Alternatives When:

Any absolute contraindication to combined hormonal contraceptives exists 1, 2
Breakthrough bleeding persists beyond 3 cycles despite adherence 5
Patient has migraine with aura 2

Monitoring Requirements

Baseline Assessment (Before Prescribing)

Pregnancy status (urine pregnancy test) 1
Blood pressure measurement 1, 2
Thorough medical history focusing on VTE risk factors, cardiovascular disease, liver disease, migraine type 1, 2
Breast and pelvic examinations including Papanicolaou smear (recommended but not mandatory per current guidelines) 1

Ongoing Monitoring

Blood pressure at each visit 1, 2
Assess for VTE symptoms at each visit (leg pain/swelling, chest pain, shortness of breath) 2
Monitor health status changes 1
No routine potassium monitoring required in healthy women 2

Management of Common Side Effects

Breakthrough Bleeding (Most Common Complaint)

Reassure patient that breakthrough bleeding typically resolves within 2-3 cycles 2, 5
Verify adherence to dosing schedule—missed pills are the primary cause of persistent bleeding 2, 5
If bleeding persists beyond 3 cycles: Rule out pregnancy, STDs, new pathologic uterine conditions, and drug interactions 5
If no underlying pathology and bleeding continues: Consider switching to alternative contraceptive method 5

Nausea

Advise taking pill with food or at bedtime 2
Reassure that nausea generally resolves within first few cycles 2

Breast Tenderness

Typically resolves spontaneously within 2-3 cycles 2
Rarely necessitates discontinuation 2

Alternative Contraceptive Options

If Switching Due to Persistent Bleeding

Levonorgestrel intrauterine device (IUD): Excellent contraceptive efficacy with eventual amenorrhea in most users, though initial irregular bleeding is common 5
Estetrol 15mg/drospirenone 3mg: Demonstrates regular scheduled bleeding patterns without blood pressure effects of synthetic estrogens 5

If Switching Due to VTE Risk Concerns

Levonorgestrel-containing COCs: 50-80% lower VTE risk than drospirenone formulations 2, 4
Progestin-only pills (POPs): No estrogen component, lower VTE risk 5
Non-hormonal methods: Copper IUD, barrier methods 5

Critical Pitfalls to Avoid

Do not prescribe Yaz to women with ANY VTE risk factors—the 50-80% higher VTE risk compared to levonorgestrel makes this unacceptable 2, 4
Do not require routine potassium monitoring in healthy women—large studies show no increased hyperkalemia risk 2
Do not avoid tetracycline antibiotics in Yaz users—they do NOT reduce contraceptive effectiveness 1
Do not switch contraceptives for breakthrough bleeding before 3 cycles—most cases resolve spontaneously 2, 5
Do not continue Yaz if new-onset migraine with aura develops—this is an absolute contraindication requiring immediate cessation 2
Do not prescribe to smokers ≥35 years old—cardiovascular risk is unacceptably high 1, 2
Do not assume blood pressure will rise—drospirenone uniquely lowers BP in most users, unlike other progestins 2, 4

Timeline for Therapeutic Effects

Contraceptive Efficacy

Immediate if started within 5 days of menstrual period 6
Backup contraception needed for 7 days if started at other times 6

Acne Improvement

Statistically significant improvement by end of cycle 3 1
Mean 79.9% reduction in total acne lesion count by cycle 6 3
Patients should be educated that acne reduction may not be appreciated for first few months 1

PMDD Symptom Relief

Significant improvement in emotional and physical symptoms by cycle 3 7, 8

Dysmenorrhea Improvement

Mean 31.2 mm reduction in pain severity (visual analog scale) by cycle 6 3

What are the common and serious adverse effects, contraindications, and alternative contraceptive options for Yaz (drospirenone/ethinyl estradiol) combined oral contraceptive in otherwise healthy adult women?

Help us tailor your experience